VNT-101 

VNT-101 is an orally active influenza A (IAV) inhibitor. VNT-101 disrupts NP-NP PPI to block NP oligomerization and destabilize the viral ribonucleoprotein (RNP) complex, with potent antiviral activity across multiple influenza A subtypes. VNT-101 exhibits EC₅₀ values of 4-5 nM in cellular cytopathic effect (CPE) assay, 4-8 nM in neuraminidase (NA) assay, and 21-45 nM in RNP assay. VNT-101 demonstrates robust in vivo antiviral efficacy in mice infected with lethal H1N1 virus. VNT-101 can be used for the study of influenza A infection^[1].

VNT-101 在 RNP 实验中表现出强效的抗流感 A 病毒活性，对 H1N1/California 亚型 EC₅₀ = 45 nM，对 H3N2/Alaska 亚型 EC₅₀ = 21 nM^[1]。
VNT-101 在 NA 实验中对病毒神经氨酸酶显示出强烈的抑制作用，对 H1N1/PR8 亚型 EC₅₀ = 8 nM，对 H3N2/Alaska 亚型 EC₅₀ = 4 nM^[1]。
VNT-101 在 CPE 实验中有效抑制病毒诱导的细胞病变效应，对 H1N1/PR8 亚型 EC₅₀ = 5 nM，对 H3N2/Alaska 亚型 EC₅₀ = 4 nM^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

VNT-101 (1-30 mg/kg，口服给药，每日两次，持续 5 天) 在感染 H1N1 病毒的 Balb/c 小鼠中发挥抗流感作用^[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

456.41

C₂₁H₂₃F₃N₂O₆

2894060-67-2

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Taft BR, et al. Discovery and Optimization of a Novel Series of Influenza A Virus Replication Inhibitors Targeting the Nucleoprotein Protein-Protein Interaction. J Med Chem. 2025 Aug 14;68(15):16349-16370.  [Content Brief]